J&J ordered to pay $5m over false marketing claims
pharmafile | April 6, 2017 | News story | Sales and Marketing | J&J, JJ, lawsuit
Johnson & Johnson has become embroiled in yet another class-action lawsuit concerning its products; this time the company is accused of falsely claiming its baby bedtime bath products are “clinically proven” to aid sleep, despite no evidence to support this.
On behalf of consumers who followed the ‘three-step nightly routine’ and experienced no positive results, product liability attorneys Parker Waichman have ordered J&J to pay $5 million on the basis that the company “knew or should have known, at the time it began selling the products, that there are no studies showing that the bedtime products are clinically proven to provide any results and [Johnson & Johnson] has no basis to make the claims about its products.”
The settlement boils down to J&J’s agreement to pay £3 per product, despite its denial of all allegations. Class members are netitled to up to $30 with proof of purchase and up to $15 without. All remaining funds from the $5 million settlement will be donated to the Nurse Family Partnership and Newborns in Need.
This legal blow is just the latest in a series of legal blows to J&J, which has been tarred by a number of lawsuits over the past year. In October, J&J was forced to pay out $70 million over allegations that the use of its baby powder had caused the development of ovarian cancer. In December, it was demanded to pay $1 billion over 8,400 lawsuits claiming its hip implants were defective and caused bone erosion and tissue death. Then, in February, it was hit with accusations that its faulty MemoryGel breast implants “may have harmed thousands of women”.
Matt Fellows
Related Content
J&J seek approval for first drug to treat high-risk smoldering myeloma
Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and …
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …
J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression
Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application …
